Skip to main content

Ensure financial flexibility, limit refinancing risks and optimize the cost of capital are the main objectives in Fresenius’s financing strategy

Assuring financial flexibility is key to the financing strategy of the Fresenius Group. An adequate liquidity headroom maintains our financial flexibility. Our refinancing risks are limited due to a balanced maturity profile that is characterized by a broad spread of maturities with a high proportion of medium- and long-term financing up to 2033.

In addition, Fresenius SE & Co. KGaA and Fresenius Medical Care AG & Co. KGaA maintain commercial paper programs. The Fresenius Medical Care receivable securitization program offers additional financing options.

Another main objective of the Fresenius Group’s financing strategy is to optimize the weighted average cost of capital by employing a balanced mix of equity and debt and striving to achieve a net debt/EBITDA ratio within a range of 3.0 to 3.5x.

Without the closed acquisition of Ivenix and the completed acquisition of a majority stake in mAbxience as well as any further potential acquisitions, Fresenius expects the net debt/EBITDA1 ratio to be roughly on the same level as in Q3/2022 (September 30, 2022: 3.64x2; including closed acquisitions of Ivenix and mAbxience: 3.74x2).

In line with the Group’s structure, financing for Fresenius Medical Care and for the rest of the Fresenius Group is conducted separately. There are no joint financing facilities and no mutual guarantees.

1 At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; excluding further potential acquisitions; before special items; including lease liabilities
2 At LTM average exchange rates for both net debt and EBITDA; pro forma closed acquisitions/divestitures; before special items; including lease liabilities

 

 

Net debt/EBITDA1
2002 – 2019 excluding IFRS 16

 

1 At actual FX rates from 2002 to 2010 and at average FX rates from 2011 onwards, for both Net Debt and EBITDA; before special items; pro forma closed acquisitions/divestitures

2 Pro forma excluding advances made for the acquisition of hospitals from Rhön-Klinikum AG

3 Including IFRS 16

Contact

Elisabeth Truckenbrodt

Director Investor Relations & Sustainability
T: +49 (0) 6172 608-2486
elisabeth.truckenbrodt@fresenius.com

Share Price

Data is delayed by 15 minutes.

Share Price Information

Related Links

Interactive Tool

Event

February 22, 2023 - 01:30 pm | Bad Homburg, Germany

Conference Call Full Year Results 2022, Fresenius

Live Webcast

Import (ICS)